Status:
SUSPENDED
Study of Minimally-invasive Ablative Renal Therapies (SMART) Registry
Lead Sponsor:
University of Alberta
Conditions:
Renal Cancer
Eligibility:
All Genders
18+ years
Brief Summary
Multi-center prospective cohort study examining curative intent renal cryotherapy and radiofrequency ablation for small renal mass treatment in patients who are poor candidates for surgical resection,...
Detailed Description
Currently the standard-of-care for non-operative renal masses which require treatment is curative ablative therapy. Curative ablative therapies include radiofrequency ablation (RFA) and cryotherapy. A...
Eligibility Criteria
Inclusion
- Adults with prior kidney tumor diagnosis;
- Willing to permit provincial agencies (e.g Alberta Health Services, Alberta Health, Netcare, Service Alberta) to disclose health-related information to study;
- Canadian and Albertan residents;
- Signed informed consent.
Exclusion
- Unwilling to participate in the study;
- Unavailable for standard clinical urological care or follow-up in Alberta
Key Trial Info
Start Date :
April 1 2022
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
December 31 2031
Estimated Enrollment :
750 Patients enrolled
Trial Details
Trial ID
NCT05210933
Start Date
April 1 2022
End Date
December 31 2031
Last Update
March 25 2025
Active Locations (2)
Enter a location and click search to find clinical trials sorted by distance.
1
University of Calgary
Calgary, Alberta, Canada
2
University of Alberta
Edmonton, Alberta, Canada